Table 3.

Characteristics associated with flare following discontinuation of TKI. TKI (tyrosine kinase inhibitor)

Clinical Characteristic	Number	% Flare	p-value
Exon 19 deletion	41	22%	1
Exon 21 L858R	19	21%
T790M	33	18%	0.5
No T790M	19	26%
First-line TKI alone	29	34%	0.06
First-line chemo	32	13%
TKI only	20	30%	0.5
Chemo	41	20%
Symptoms of disease progression	20	40%	0.05
No symptoms	41	15%
Karnofsky Performance Status 70%	11	36%	0.4
Karnofsky Performance Status 80-90%	50	22%
CNS involvement	14	50%	0.01
No CNS disease	47	15%
Bone involvement	31	26%	0.8
No bony disease	30	20%
Pleural involvement	36	33%	0.03
No pleural disease	25	8%
Male	13	15%	0.7
Female	48	25%
Erlotinib	40	33%	0.3
Gefitinib	11	9%
Current/Former Smoker	12	16%	0.7
Never smoker	49	24%